Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMSA101 + PULSAR-ICI in Oligoprogressive Solid Tumors
NCT05846659Phase 2Terminated
- Sponsor
- ImmuneSensor Therapeutics
- Start
- Jul 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of IMSA101 in solid tumor (2 arms), sponsored by ImmuneSensor Therapeutics. Primary endpoint: Anti-tumor Effects at 12 months. Started Jul 2023; status: terminated.
02
Drugs
IMSA101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05846659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846659.